Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka
preprint
OA: gold
CC-BY-NC-ND-4.0
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (25)
- A Rapid Antibody Screening Haemagglutination Test for Predicting Immunity to Sars CoV-2 Variants of Concern via crossref
- Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study via crossref
- Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa via crossref
- Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals via crossref
- Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals via crossref
- Plasma neutralization properties of the SARS-CoV-2 Omicron variant via crossref
- SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection via crossref
- Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK via crossref
- doi:10.1038/s41587-020-0631-z via crossref
- doi:10.1056/nejmoa2108453 via crossref
- doi:10.1016/s2666-5247(21)00025-2 via crossref
- doi:10.1056/nejmc2113468 via crossref
- doi:10.1016/s0140-6736(21)02249-2 via crossref
- doi:10.1016/j.ijid.2021.06.031 via crossref
- doi:10.1038/s41541-021-00369-6 via crossref
- doi:10.1128/jvi.00203-21 via crossref
- doi:10.1038/d41586-021-03592-2 via crossref
- doi:10.1038/d41586-021-01609-4 via crossref
- doi:10.1016/s1473-3099(20)30120-1 via crossref
- doi:10.1038/s41591-021-01377-8 via crossref
- doi:10.1016/j.chom.2021.11.004 via crossref
- doi:10.1056/nejmc2115596 via crossref
- doi:10.4038/sljpm.v2i2.42 via crossref
- doi:10.1111/trf.16600 via crossref
- doi:10.1016/s2666-5247(21)00267-6 via crossref
Source provenance
- crossref
- last seen: 2026-06-05T01:00:36.979803+00:00
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-05-21T02:00:01.467718+00:00
License: CC-BY-NC-ND-4.0